Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome
NCT ID: NCT00728988
Last Updated: 2021-02-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
499 participants
INTERVENTIONAL
2008-09-30
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting
NCT02565615
Efficacy Study of Atorvastatin to Treat Variant Angina
NCT00620204
Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention
NCT00610870
Sequential Therapy of Atorvastatin Improve Outcomes of ST-elevated Acute Myocardial Infarction
NCT01997294
Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study
NCT00469326
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atorvastatin Group
Atorvastatin
80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
Usual Care Group
Atorvastatin
40mg daily after PCI for 30 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
Atorvastatin
40mg daily after PCI for 30 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Guangzhou, Guangdong, China
Pfizer Investigational Site
Changsha, Hunan, China
Pfizer Investigational Site
Shenyang, Liaoning, China
Pfizer Investigational Site
Shenyang, Liaoning, China
Pfizer Investigational Site
Qingdao, Shandong, China
Pfizer Investigational Site
Hangzhou, Zhejiang, China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Seongnam-si, Gyeonggi-do, Korea, South Korea
Pfizer Investigational Site
Busan, , South Korea
Pfizer Investigational Site
Daegu, , South Korea
Pfizer Investigational Site
Daegu, , South Korea
Pfizer Investigational Site
Daegu, , South Korea
Pfizer Investigational Site
Daejeon, , South Korea
Pfizer Investigational Site
Gangneung-si, Gangwon-do, , South Korea
Pfizer Investigational Site
Gwangju, , South Korea
Pfizer Investigational Site
Jinju-si, Gyeongsangnam-do, , South Korea
Pfizer Investigational Site
Koyang-shi, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Ulsan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jang Y, Zhu J, Ge J, Kim YJ, Ji C, Lam W. Preloading with atorvastatin before percutaneous coronary intervention in statin-naive Asian patients with non-ST elevation acute coronary syndromes: A randomized study. J Cardiol. 2014 May;63(5):335-43. doi: 10.1016/j.jjcc.2013.09.012. Epub 2013 Nov 9.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2581161
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.